The firstasymmetricsynthesis of phenanthroquinolizidine alkaloid (R)-boehmeriasin A is described. Two alternative synthetic pathways to the key intermediate (RS,R)-4 were achieved through a combination of highly diastereoselective 1,2-nucleophilic addition on (―)-(S)-1-amino-2-(methoxymethyl)pyrrolidine hydrazones with a ring-closing metathesis to ensure the construction of the piperidine template
描述了菲喹唑啶生物碱 (R)-勃姆菌素 A 的第一个不对称合成。通过对 (-)-(S)-1-氨基-2-(甲氧基甲基)吡咯烷腙进行高度非对映选择性的 1,2-亲核加成与闭环复分解,以确保哌啶模板的构建。随后的酰化/氧化/羟醛缩合/自由基环化序列完成了标题 (R) 配置的天然产物的组装。
Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2
作者:Michael S. Christodoulou、Francesco Calogero、Marcus Baumann、Aída Nelly García-Argáez、Stefano Pieraccini、Maurizio Sironi、Federico Dapiaggi、Raffaella Bucci、Gianluigi Broggini、Silvia Gazzola、Sandra Liekens、Alessandra Silvani、Maija Lahtela-Kakkonen、Nadine Martinet、Alfons Nonell-Canals、Eduardo Santamaría-Navarro、Ian R. Baxendale、Lisa Dalla Via、Daniele Passarella
DOI:10.1016/j.ejmech.2015.01.038
日期:2015.3
Two synthetic approaches to boehmeriasin A are described. A gram scale racemic preparation is accompanied by an efficient preparation of both the pure enantiomers using the conformationally stable 2-piperidin-2-yl acetaldehyde as starting material. The anti-proliferative activity in three cancer cell lines (CEM, HeLa and L1210) and two endothelial cell lines (HMEC-1, BAEC) indicates promising activity at the nanomolar range. Topoisomerases and SIRT2 are identified as biological targets and the experimental data has been supported by docking studies. (C) 2015 Elsevier Masson SAS. All rights reserved.